EP300 and cancer: Inhibition of CARM1 activity slows diffuse large B-cell lymphoma (DLBCL) growth, which is positively correlated with CBP/P300-mutation status, indicating that the CBP/P300 mutation in cancer creates a vulnerability to targeting CARM1 activity.